Can Patents Deter Innovation? The. Anticommons in Biomedical Research The tragedy of the anticommons is the underuse of a scare resource because the. Can patents deter innovation?: An empirical analysis of the anti-commons effect in the academic biomedical research in Milan Paperback – January 16, Heller and Eisenberg are reacting, in large part, to the growth of patenting within in biomedical science (see Murray () for more detail on.

Author: Nikole Mulkis
Country: Ghana
Language: English (Spanish)
Genre: Literature
Published (Last): 2 September 2016
Pages: 46
PDF File Size: 19.77 Mb
ePub File Size: 3.87 Mb
ISBN: 228-8-84861-186-5
Downloads: 77390
Price: Free* [*Free Regsitration Required]
Uploader: Gardashura

Can patents deter innovation? The anticommons in biomedical research

Retrieved from ” https: Help How to edit FAQ. In that sense, Murray and Stern’s article econometric article testing the hypothesis is a somewhat rough match for the theory offered. Heller and Eisenberg are reacting, in large part, to the growth of patenting within in biomedical science see Murray for more detail on case study of this in the area of mouse-research.

Eisenberg Can patents deter innovation? Theoretical and practical relevance: Heller and Eisenberg’s article has been cited more than 1, times researchh the last 12 years and has become a major article in the literature critical of patents in science.


Their core argument is that the anticommons emerges when the rights necessary to practice research are split up among a large number, and a large variety, of different researchers.

Can patents deter innovation? The anticommons in biomedical research.

Views Read View form View source View history. This essentially introduces a set of complex collective action problems beyond those introduced by patent licensing which they suggest may create an important barrier to scientific progress.

New Recent Changes Featured Summaries. They argue that just detdr too much open access to an expendable public resource can create a tragedy of the commons, too much ownership — especially an intellectual domain — can create thickets that limit the progress of science more broadly.

Can patents deter innovation? The anticommons in biomedical research.

They end by describing why different types of organizations i. Privacy policy About AcaWiki Disclaimers.

That said, the article seems to be somewhat missued by a number of “downstream” academics citing it. The article was also tested by Walsh et al.

Can Patents Deter Innovation? The Anticommons in Biomedical Research

They argue that, “privatization can solve one tragedy but cause another. This page was last modified on 11 Octoberat The anticommons in biomedical research. Anticommone explain quite clearly that, “the tragedy of the anticommons refers to the more complex obstacles that arise when a user needs access to multiple patented inputs to create a single useful output.


The metaphor of the anticommons has become a frequently cited in the areas of open innovation, arguments in favor of open science, and critiques of the patent system more generally. The article is often treated as argument against particular patents. Content is available under Creative Commons Attribution 3.

Published in Science inHeller and Eisenberg frame their argument explicitly in terms of Hardin’s classic piece of The tragedy of the commons and applied to biomedical research although it has been used and cited as patentz more broadly. In fact, it’s argument is carefully crouched in terms of the problems of patents in aggregate.

They use examples of patents on concurrent onnovation which they suggest may be creating thickets and reach-through licensing agreements to make this point.